Moleculin Biotech, Inc. (LON: 0K2H)
London
· Delayed Price · Currency is GBP · Price in USD
1.535
0.00 (0.00%)
At close: Jan 31, 2025
Moleculin Biotech Employees
Moleculin Biotech had 18 employees as of December 31, 2023. The number of employees decreased by 1 or -5.26% compared to the previous year.
Employees
18
Change (1Y)
-1
Growth (1Y)
-5.26%
Revenue / Employee
n/a
Profits / Employee
-1.25M GBP
Market Cap
3.65M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
Shell | 103,000 |
HSBC Holdings | 220,861 |
Unilever | 128,377 |
Rio Tinto Group | 57,000 |
RELX PLC | 36,500 |
British American Tobacco p.l.c. | 46,725 |
BP p.l.c. | 87,800 |
Moleculin Biotech News
- 25 days ago - Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 - PRNewsWire
- 7 weeks ago - Moleculin Biotech files for stock and warrants offering - Seeking Alpha
- 7 weeks ago - What's Going On With Moleculin Biotech Shares Wednesday? - Benzinga
- 7 weeks ago - Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model - PRNewsWire
- 2 months ago - New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PRNewsWire
- 2 months ago - Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PRNewsWire
- 2 months ago - Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PRNewsWire
- 2 months ago - Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript - Seeking Alpha